Programa Nacional Para As Doenças Cérebro-Cardiovasculares

Objectives

The National Programme for Cerebrovascular and Cardiovascular Diseases seeks to reduce cardiovascular risk, prevent cerebro-cardiovascular disease, lessen disability and premature loss of life, and prolong life through planned, organised action across Portugal’s health system. It addresses ischaemic heart disease, acute myocardial infarction, cerebrovascular disease, and both ischaemic and haemorrhagic stroke.[1][2][3][4]Its principal prevention focus is the control of modifiable risk factors, particularly hypertension and dyslipidaemia, alongside complementary action on smoking, physical activity, diabetes and dietary salt consumption.[4]

• Reduce premature mortality before age 70 from cerebrovascular disease to a standardised mortality rate below 8.5% or fewer than 1,000 deaths, and from ischaemic heart disease to below 9.5% or fewer than 1,000 deaths.[4]
• Reduce in-hospital mortality from acute myocardial infarction to 7%, corresponding to fewer than 950 annual deaths.[2][4]
• Increase primary angioplasty for acute myocardial infarction to 470 procedures per million inhabitants.[2][4]
• Increase thrombolytic or endovascular reperfusion treatment for stroke to 1,800 cases annually.[2][4]
• Reduce population salt consumption by 3% to 4% annually over four years, jointly with the Healthy Eating Promotion Programme.[2][4]
• Maintain ischaemic heart disease as a priority, as overall mortality had not improved over the preceding five years and premature mortality among people under 70 had worsened.[5]
• Build on progress in cerebrovascular disease, for which stroke deaths fell by 39% between 2011 and 2015 and the premature ischaemic-stroke mortality target was exceeded.[1][6]

The programme frames these priorities against a substantial burden of disease: cardiovascular diseases accounted for 29.7% of all deaths in Portugal in 2015 and remained a major cause of morbidity, disability, invalidity and premature death.[5][3]Although mortality from circulatory diseases had progressively declined, hospital admissions for heart disease increased by 26% between 2011 and 2015, and population ageing was identified as likely to increase heart-failure admissions and pressure on resource allocation.[1][7]

Implementation

Implementation combines risk-factor prevention, primary care, emergency referral, hospital treatment, surveillance, clinical standards and research. The programme aims to align institutions around appropriate acute myocardial infarction and stroke care, strengthen pre-hospital emergency performance, and reduce deaths occurring before hospital admission.[8][4][9]Key actors identified include the Directorate-General of Health, National Institute of Medical Emergency, National Health Service, health units, Central Administration of the Health System, National Statistics Institute, National Authority of Medicines and Health Products, and National Programme for the Promotion of Healthy Eating.[10][11][8]

• Operate rapid-referral Via Verde pathways through the National Institute of Medical Emergency for suspected stroke and acute myocardial infarction, supporting prompt referral and reduced treatment delays.[11]
• Improve primary-care management of hypertension and dyslipidaemia, support appropriate use of antihypertensive, lipid-lowering and anticoagulant or antithrombotic medicines, and raise awareness of myocardial infarction warning signs.[11][12]
• Expand access to fibrinolysis, primary angioplasty and other revascularisation procedures, while monitoring the national coverage and future development of endovascular stroke treatment.[7][10][12]
• Consolidate stroke units and support thromboprophylaxis in atrial fibrillation through non-vitamin K antagonist oral anticoagulants.[6]
• Coordinate salt-reduction measures with the healthy-eating programme by monitoring salt content in major foods, supporting legislative and food-sector self-regulatory action, communicating reliable information, training health professionals and developing primary-care interventions.[13]
• Validate referral networks for stroke and cardiology, survey health units on coronary and stroke emergency pathways, and work with the Directorate-General of Health’s Department of Quality in Health to revise relevant standards.[8]
• Develop a remote interpretation and analysis centre for cardiovascular diagnostic and therapeutic tests, linking primary-care groups with specialist hospital units; a pilot implementation phase involving the Central Lisbon Hospital Centre and Lisbon and Tagus Valley Regional Health Administration took place in the first half of 2017.[3]
• Support cardiac rehabilitation planning, cooperate with professional and scientific societies, and participate in the European ERA-NET Cardiovascular Disease research partnership with the Foundation for Science and Technology.[12]

Monitoring uses national statistical, hospital-discharge, medicine, emergency-service and health-unit survey data.[8][9]The framework follows mortality, hospital admissions, in-hospital myocardial-infarction deaths, angioplasty and stroke-treatment activity, salt content and consumption, and Via Verde referral performance.[2][10][11][9]Direct access to the SICO information system is intended to identify material deviations from mortality targets and enable corrective action.[13]The supplied material does not specify a dedicated budget, financing source, formal reporting timetable, or comprehensive accountability structure.[8][3][4][9][13][12]

Monitoring & Evaluation

The monitoring framework combines population outcomes, hospital activity, emergency-pathway performance, treatment access, medicine use and dietary risk factors to assess progress towards the 2020 cardiovascular and cerebrovascular objectives.[2][4]It draws on epidemiological surveillance, national administrative data, health-unit surveys and direct access to the SICO information system to identify deviations and support corrective action.[8][13]

• Track mortality from circulatory diseases, ischaemic heart disease, acute myocardial infarction and cerebrovascular disease, including standardised premature mortality among people aged under 70.[5][6]
• Measure progress towards reducing premature cerebrovascular mortality to a standardised rate below 8.5% or fewer than 1,000 deaths, and premature ischaemic heart disease mortality to below 9.5% or fewer than 1,000 deaths.[4]
• Monitor in-hospital acute myocardial infarction mortality against the 7% target and the objective of fewer than 950 annual deaths.[4]
• Measure access to acute treatment through primary angioplasty for myocardial infarction, targeted at 470 procedures per million inhabitants, and thrombolytic or endovascular stroke reperfusion treatment, targeted at 1,800 cases annually.[4]
• Track annual reductions in population salt consumption, with a target reduction of 3% to 4% each year, alongside the average salt content supplied by major food groups.[4][9]
• Monitor hospital admissions and deaths for heart failure, ischaemic stroke and haemorrhagic stroke, as well as broader circulatory disease and acute myocardial infarction trends.[7][10]
• Assess treatment volumes and patterns, including stroke fibrinolysis, primary angioplasty relative to fibrinolysis for myocardial infarction, and percutaneous angioplasty relative to coronary surgery.[10]
• Measure the Via Verde emergency-referral pathways through referral volumes, geographical distribution and the proportion of patients referred within two hours of symptom identification.[11]In 2016, the stroke pathway recorded 3,386 referrals; by September 2017, 2,301 stroke referrals had been recorded and 80.7% were referred within two hours.[11]The myocardial infarction pathway recorded 444 referrals by September 2017, of which 75.9% were referred within two hours.[11]
• Use National Statistics Institute data, Central Administration of the Health System hospital-discharge data, National Authority of Medicines and Health Products data, National Institute of Medical Emergency data, SICO and programme data to support analysis.[8][9]
• Apply rates per 100,000 inhabitants and International Classification of Diseases, 10th Revision coding in the reported mortality analyses.[5][6][14]
• Validate stroke and cardiology referral networks and monitor coronary and stroke emergency pathways through health-unit surveys and service-performance assessment.[8]

Reported results provide a baseline for performance review: cardiovascular disease accounted for 29.7% of all deaths in Portugal in 2015; stroke deaths fell by 39% between 2011 and 2015; and premature ischaemic stroke mortality declined by 39%, exceeding the established target.[5][1][6]Hospital admissions for heart disease rose by 26% between 2011 and 2015, indicating that mortality improvement should be interpreted alongside service demand.[1]

Accountability is principally operational: monitoring mortality targets and sectoral indicators is intended to flag significant deviations and enable corrective measures.[13]The supplied material does not specify a reporting timetable, formal public reporting arrangements, named accountable officers or a dedicated independent evaluation framework.[8][3][4]

Costing & Financing

No explicit programme budget, costed implementation plan, financing source, funding gap, resource-mobilisation mechanism or quantified economic assumption is provided in the supplied material.[8][9][13][12]

• Recognise medicines as a financially significant component of National Health Service expenditure; increased use of antihypertensive and lipid-lowering medicines reportedly coincided with lower overall expenditure because of reduced unit costs and greater use of less expensive medicines.[11]
• Consider population ageing in future resource allocation, as it is expected to increase heart-failure admissions and affect the distribution of available resources.[7]
• Use salt reduction as a prevention measure characterised in the World Health Organization European framework as low cost and highly effective, although no monetary estimate is supplied.[4]
• Note that the source identifies resource-relevant activities, including emergency referral pathways, primary angioplasty, stroke reperfusion treatment, remote cardiology analysis, referral-network validation, research participation and cardiac rehabilitation planning, but does not assign costs or funding to them.[8][12]

The evidence therefore supports qualitative consideration of cost pressures and potential efficiency measures, but not calculation of programme affordability, budget requirements, savings, unit costs or financing shortfalls.[7][11][4]